Pollinex^® Quattro: a novel and well–tolerated, ultra short–course allergy vaccine

Abstract

Pollinex^® Quattro is a novel, ultra short-course vaccine for treatment of seasonal allergic rhinitis from grass, tree or ragweed pollen allergy. Its unique formulation combines chemically modified allergens adsorbed onto a L-tyrosine depot to enhance tolerability with the novel adjuvant, monophosphoryl lipid A, to improve efficacy. Controlled clinical studies indicate that four preseasonal injections with grass or tree formulations significantly reduce rhinoconjunctivitis symptoms and medication use, as well as elevate allergen-specific immunoglobulin G and blunt elevation of immunoglobulin E upon allergen exposure. Postmarketing surveillance studies indicate similar clinical outcomes. In all cases, the allergy vaccine was well tolerated with minimal local reactions, while systemic reactions were rare and mild. Results from recent investigational trials with grass and ragweed formulations are consistent with previous efficacy and safety outcomes, and will be used toward product registration in North America.

Keywords::

• adjuvant
• allergen
• allergic rhinitis
• allergoid
• allergy vaccine
• asthma
• L-tyrosine depot
• monophosphoryl lipid A
• Pollinex^® Quattro
• sublingual allergen-specific immunotherapy